Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 19 Sept 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Valion Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VBIO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Valion Bio, Inc. returned −97.3% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 76% of US stocks
Cheaper than 99% of US stocks
Cheaper than 41% of US stocks
Cheaper than 68% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 99% of US stocks
Higher than 30% of US stocks
Higher than 3% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Valion Bio, Inc. has a market value of $2.0M and an enterprise value of $17.3M.
Revenue in the twelve months to 30 June 2026: −$156K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$18.8M, a 12019.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$14.7M.
Trailing P/E: −0.0×.
Valion Bio, Inc. employs 52 people — −$3K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Valion Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Valion Bio announced changes to its management and board of directors, with current CFO Lisa Wolf named President and COO with expanded executive and operational leadership. Jared Malbin and Thomas Jensen were appointed as directors.
Why it matters — VBIO watchers would care as leadership and board changes could influence the company's strategic direction and governance.
Valion Bio, Inc. announced that its Board of Directors declared a 1-for-25 reverse stock split of the company's issued and outstanding shares of common stock. The split is intended to bring the company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Why it matters — A reverse stock split is a corporate action that consolidates the share count and raises the per-share price, which VBIO watchers would follow because it reflects the company's effort to maintain its Nasdaq listing and address continued-listing compliance.
Ukraine's Ministry of Health accepted Entolimod's dossier for formal review on July 22, 2026, and has begun a technical assessment that includes its first round of questions on the physicochemical characterization of the drug product. A decision is possible as early as the fourth quarter of 2026, which could mark Entolimod's first national registration.
Why it matters — A VBIO watcher would care because a potential Q4 2026 decision in Ukraine could mark Entolimod's first national registration and open a pathway to strategic stockpiling and government procurement.
Valion Bio announced U.S. government-funded entolimod studies under an AFRRI/NIAID program targeting lethal radiation-induced gastrointestinal injury. Entolimod has been delivered to AFRRI, IACUC approval was obtained, study animals are being acclimated, and dosing is expected to begin this week, with top-line therapeutic data expected in early fall.
Why it matters — VBIO watchers would follow this as evidence of forward progress in the company's key entolimod development program, backed by U.S. government funding and with clinical milestones on the near-term horizon.
As at 19 Sept 2026, Valion Bio, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
No analyst covering Valion Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VBIO are extrapolating price history, which says nothing about the business.
Valion Bio, Inc. returned -97.3% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company.
The most recent item we track (Accesswire, 1 Sept 2026): "Valion Bio Announces Changes to Management and Board of Directors". Valion Bio announced changes to its management and board of directors, with current CFO Lisa Wolf named President and COO with expanded executive and operational leadership. Jared Malbin and Thomas Jensen were appointed as directors.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
CEO Mr. Michael Kevin Handley · 52 employees · United States · https://valionbio.com
